Fast patient
Proof of concept trials

PROOF OF CONCEPT TRIALS

proof of concept trials

ARENSIA delivers high degree of scientific and logistical expertise for Phase I/Ib/IIa and PROOF OF CONCEPT patient studies.

MORE

COVID-19 RESEARCH

COVID-19 RESEARCH

ARENSIA has contributed to numerous research projects with innovative compounds enrolling more than 1,500 COVID-19 patients.

MORE

REGULATORY PROCESS

regulatory process

ARENSIA has the know-how to successfully manage the regulatory process in various Eastern European countries.

MORE

ARENSIA UKRAINE RESUMES PHASE 1 TRIAL IN PATIENTS WITH MULTIPLE SCLEROSIS

HOME · NEWS · ARENSIA UKRAINE RESUMES PHASE 1 TRIAL IN PATIENTS WITH MULTIPLE SCLEROSIS

Last week, ARENSIA clinic in Ukraine resumed participation in a Phase I trial with an innovative drug targeting Multiple Sclerosis involving central imaging reading, 3 central laboratories (based in UK and EU), and sophisticated study procedures. Our extraordinary team in Kyiv has dosed the first patient in the MAD cohort. Another 2 patients shall be dosed this week. We plan to progress the project at the fastest speed. Our clinic in Kyiv has access to large pools of neurological patients, including Multiple Sclerosis. We are proud to continue offering Ukrainian patients access to the latest generation therapies!

13.03.2023
VIDEO INTRO

We use technologies, such as cookies, and process personal data, such as IP addresses and cookie identifiers, to personalise content based on your interests, measure the performance of our content, and derive insights about the audiences who saw it. You can read more about our Cookie Policy here.

I accept I refuse